Cargando…

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells

BACKGROUND: As heterogeneous tumors develop in the face of intact immunity, tumor cells harboring genomic or expression defects that favor evasion from T-cell detection or elimination are selected. For patients with such tumors, T cell-based immunotherapy alone infrequently results in durable tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Maxwell Y, Robbins, Yvette, Sievers, Cem, Friedman, Jay, Abdul Sater, Houssein, Clavijo, Paul E, Judd, Nancy, Tsong, Edward, Silvin, Chris, Soon-Shiong, Patrick, Padget, Michelle R, Schlom, Jeffrey, Hodge, James, Hinrichs, Christian, Allen, Clint
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986659/ https://www.ncbi.nlm.nih.gov/pubmed/33741731 http://dx.doi.org/10.1136/jitc-2020-002128

Ejemplares similares

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes
por: Sievers, Cem, et al.
Publicado: (2021)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
por: Friedman, Jay, et al.
Publicado: (2018)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity
por: Hong, Youji, et al.
Publicado: (2022)

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
por: Wolfson, Benjamin, et al.
Publicado: (2021)

The Atypical Chemokine Receptor Ackr2 Constrains NK Cell Migratory Activity and Promotes Metastasis
por: Hansell, Christopher A. H., et al.
Publicado: (2018)

ZEB1 transcription factor promotes immune escape in melanoma
por: Plaschka, Maud, et al.
Publicado: (2022)

Loss of NKG2D in murine NK cells leads to increased perforin production upon long‐term stimulation with IL‐2
por: Prinz, Daniela, et al.
Publicado: (2020)

N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor
por: Lou, Chao, et al.
Publicado: (2022)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2022)

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
por: Redman, Jason M., et al.
Publicado: (2023)

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
por: Torres, Nicolas, et al.
Publicado: (2020)

Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer
por: Hagel, Kimberly R., et al.
Publicado: (2023)

High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome
por: Wolf, Dominik, et al.
Publicado: (2019)

LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs
por: Xia, Rongmu, et al.
Publicado: (2021)

The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity
por: Tumino, Nicola, et al.
Publicado: (2022)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

SUN-331 Clinical Characteristics and Genotype-Phenotype Analysis of MEN1 Patients with Thymic Neuroendocrine Tumors
por: Mandl, Adel, et al.
Publicado: (2019)

MON-913 Testosterone Secreting Ovarian Tumor: A Rare Cause of Erythrocytosis and Pulmonary Embolus
por: Friedman, Naomi, et al.
Publicado: (2020)

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells
por: Zhuang, Xiaoxuan, et al.
Publicado: (2022)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
por: Neo, Shi Yong, et al.
Publicado: (2022)

Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
por: Heeren, Anne Marijne, et al.
Publicado: (2021)

Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities
por: Chan, Jack D., et al.
Publicado: (2020)

IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells
por: Landolina, Nadine, et al.
Publicado: (2022)

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
por: Cornel, Annelisa M, et al.
Publicado: (2022)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches
por: Allen, Clint T., et al.
Publicado: (2015)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
por: Bernard, Pierre-Louis, et al.
Publicado: (2022)

A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
por: Bellmann, Lydia, et al.
Publicado: (2019)

PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling
por: Raja, Remya, et al.
Publicado: (2022)

2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis
por: Pan, Banglun, et al.
Publicado: (2023)

THU476 Role Of Mitochondrial Sirtuins 3 And 5 On Glutamine Addiction In Prostate Cancer Cell
por: Hasan, Kamrul M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vmirt2viecpuk7nai45dnel0p9